EUROPEAN COMMISSION
ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL

Consumer Goods and EU Satellite navigation programmes
Competitiveness in the Pharmaceuticals Industry and Biotechnology

Minutes of the meeting with stakeholders on the process on corporate responsibility in the field of pharmaceuticals 20 July 2010

The meeting was organised to present the process on corporate responsibility in the field of pharmaceuticals to the concerned stakeholders. The meeting was chaired by Ms Lalis, Director for consumer goods and EU satellite navigation programmes.

Were present:

- Nathalie Moll, EuropaBio; [redacted], EuropaBio; [redacted], ESIP; [redacted], EGA; [redacted] EFPIA; Monika Derecque-Pois, GIRP; Hubertus Cranz, AESGP; John Chave, PGEU; Birgit Berger, CPME; [redacted], EPF; [redacted], AIM; [redacted], MSF; [redacted], MSF.

- Georgette Lalis, [redacted], [redacted], DG Enterprise.

The process on corporate responsibility in the field of pharmaceuticals was introduced by Ms Lalis (see the presentation annexed).

The process will focus on Access to medicines after the grant of their marketing authorisation and on corporate social responsibility in the field of pharmaceuticals. Three pillars will indeed be set up: (1) Transparency and deontology, (2) Access to medicines in least developed countries and (3) Access to medicines in Europe. Each pillar will have a set of projects in which volunteering members (stakeholders and Member States) will be invited to contribute.

It was explained that the projects on access to medicines in Europe were well developed as they were based on some of the recommendations of the Pharmaceutical Forum on pricing and reimbursement as well as on the discussions that took place during informal workshops organised by the Commission services. The projects presented in relation to access to medicines in Africa were still to be identified and should be further developed according to the needs expressed by the concerned third countries. For both pillars on Access to medicines in least developed countries and on Transparency and deontology, informal workshops would be organised in the autumn to discuss with experts possible projects.

The participants were invited to comment and express their interest on the different projects. The inclusion of personalised medicines, vaccines and medical devices to the process was suggested. It was also emphasised the need to work with cautious on the theme ethics and transparency.

The participants will be kept informed on the development of the process.

Commission européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel - Belgium. Telephone: (32-2) 299 11 11.
Office: BREY 10/212. Telephone: direct line (32-2) [redacted] Fax: (32-2) 2921365.